Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
116.55
+4.99 (4.47%)
Nov 21, 2024, 4:00 PM EST - Market closed
Ligand Pharmaceuticals Employees
Ligand Pharmaceuticals had 58 employees as of December 31, 2023. The number of employees decreased by 18 or -23.68% compared to the previous year.
Employees
58
Change (1Y)
-18
Growth (1Y)
-23.68%
Revenue / Employee
$2,627,966
Profits / Employee
$780,069
Market Cap
2.20B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
Azenta | 3,500 |
Premier | 2,900 |
Astrana Health | 1,800 |
Amphastar Pharmaceuticals | 1,761 |
Supernus Pharmaceuticals | 652 |
Beam Therapeutics | 436 |
Wave Life Sciences | 268 |
LGND News
- 7 days ago - Ligand to Present at Stifel 2024 Healthcare Conference - Business Wire
- 13 days ago - Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance - Business Wire
- 20 days ago - Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston - Business Wire
- 4 weeks ago - Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 - Business Wire
- 2 months ago - Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy - Business Wire
- 2 months ago - CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030 - GlobeNewsWire
- 3 months ago - Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference - Business Wire